Who Paid My Doc
Avanir Pharmaceuticals, Inc.
CA, United States
CMS manufacturer 100000005729
General payments
$6,688,438
Research payments
$32,837,486
Ownership & investment interest
$0
Through program year 2022, Avanir Pharmaceuticals, Inc. reported paying $6,688,438 in general payments and $32,837,486 in research payments to U.S. physicians, teaching hospitals and other recipients.
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | General | $1,074,682 | 22,404 |
| 2022 | Research | $1,454,215 | 941 |
| 2021 | General | $1,440,627 | 19,937 |
| 2021 | Research | $5,599,621 | 810 |
| 2020 | General | $634,876 | 6,860 |
| 2020 | Research | $5,538,864 | 758 |
| 2019 | General | $3,538,252 | 30,198 |
| 2019 | Research | $20,244,786 | 1,210 |
Breakdown
Each share is of this company’s general payments naming a product in 2022. A payment can name up to five products, so these amounts overlap.
The top 5 of 119 specialties; each share is of this company’s general payments to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
The top 5 of 47 states; each share is of this company’s general payments in 2022 where a state was reported.
Records
79,399 general · 3,719 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.